IL-7 germline variant: setting the stage for immune-related adverse events.

Autor: Issaoui H; Université Côte d'Azur, INSERM, C3M, Nice, France.; Equipe Labellisée Ligue Contre le Cancer, Nice, France., Ricci JE; Université Côte d'Azur, INSERM, C3M, Nice, France.; Equipe Labellisée Ligue Contre le Cancer, Nice, France.
Jazyk: angličtina
Zdroj: Molecular oncology [Mol Oncol] 2023 Mar; Vol. 17 (3), pp. 384-386. Date of Electronic Publication: 2023 Feb 24.
DOI: 10.1002/1878-0261.13392
Abstrakt: Treatment with immune checkpoint inhibitors (ICIs) is frequently associated with immune-related adverse events (irAEs). A new study identified an interleukin 7 (IL-7) allelic variant-rs16906115-as a major risk factor for the development of ICI-associated irAEs. This association is of great significance as it indicates that germline genetic variants influence the occurrence of irAEs, thus opening a new avenue for identifying high-risk patients to enable better management of ICI therapy and associated irAEs.
(© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
Databáze: MEDLINE
Externí odkaz: